Cancer Therapy
Silibinin limits doxorubicin-induced toxicity in murine tumor models
Published in Cancer Weekly, March 8th, 2005
"The acute and cumulative dose-related toxicity and drug resistance, mediated via nuclear factor kappa B (NFkappaB), of anthracycline anticancer drugs pose a major problem in cancer chemotherapy," according to scientists in the United States.
"Here, we report that oral silibinin (a flavanone) suppresses human non-small-cell lung carcinoma A549 xenograft growth (p=0.003) and enhances the therapeutic response (p<0.05) of doxorubicin in athymic BALB/c nu/nu mice together with a strong prevention of doxorubicin-caused adverse health effects," wrote R.P. Singh and colleagues,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2005-03-08)
More Articles from Cancer Weekly
- Diagnostics
Gene methylation analysis has potential as tool in cervical cancer screening - Hepatocellular Carcinoma
Clusterin overexpression has prognostic value - Pancreatic Cancer
Novel putative protein biomarkers and therapeutic targets identified - Prostate Cancer
High heterogeneity found in metastatic hormone-resistant disease - Tabacco Use
Genotoxicity of tobacco smoke and tobacco smoke condensate reviewed - Acute Lymphoblastic Leukemia
Role of DNA microarrays in ALL diagnosis and treatment reviewed - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
